ArticleBreast cancer research : BCR2025
Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIdentifying treatments for triple-negative breast cancer (TNBC) remains a critical medical need. We have found that Interleukin 13 receptor alpha 2 (IL-13RA2), EphA2, EphA3 and EphB2 receptors are over-expressed collectively in majority of patients with breast cancer and its brain metastases. We are pursuing the novel idea of targeting these four tumor-associated receptors identified by us with one pharmaceutical compound. A compound, called QUAD, was designed and constructed, which binds all four targeted receptors.
methodsWe have examined the presence of IL-13RA2, EphA2, EphA3 and EphB2 receptors in breast cancer cells in vitro, tissue micro-arrays including involved lymph nodes, and in paired primary tumor-brain metastases, including two subtypes of breast cancer. We also tested the activity of the quadrivalent ligand, QUAD, conjugated to a derivative of maytansine, DM1, in vitro and in vivo.
resultsWe have found that the four target receptors are frequently over-expressed in breast cancer, including TNBC and (HER2)-positive breast cancers and related metastases to the brain. This is based on the observed expression levels for the genes and the gene products; a combined expression of our target of interest approaches 100% of specimens' positivity. Furthermore, several TNBC cell lines were killed at low concentrations of QUAD-DM1 conjugate. MDA-MB-231 tumors growing in mammary pads of athymic mice responded significantly to a dose of 12 mg/kg (3x). MDA-MB-231-BrM tumors growing intracranially also responded to 4 µg/mouse (1x) of QUAD-DM1.
conclusionsQUAD-DM1 is a novel multivalent drug conjugate that appears to be highly suitable for the treatment of breast cancer and related brain metastases. The drug candidate can be administered systemically, due to its favorable toxicity profile, or loco-regionally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.